ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ADC Therapeutics reported that its Chief Financial Officer, Jose Carmona, received an award of 203,700 restricted stock units on June 30, 2026. These RSUs vest on the earlier of June 30, 2027 or certain qualifying termination events, assuming continued employment. Each RSU converts into one common share, bringing his direct holdings to 938,076 common shares after the award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carmona Jose

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	203,700	$0.00	--

Holdings After Transaction: Common Shares — 938,076 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 203,700 units Post-grant holdings: 938,076 shares Grant price: $0.00 per unit +1 more

4 metrics

RSUs granted 203,700 units Restricted stock units granted on June 30, 2026

Post-grant holdings 938,076 shares Common shares directly owned after RSU award

Grant price $0.00 per unit RSU award under incentive agreement

Vesting date June 30, 2027 Time-based vesting unless earlier qualifying termination

Key Terms

restricted stock units ("RSUs"), incentive award letter agreement, vest, good reason, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents an award of restricted stock units ("RSUs") granted on June 30, 2026"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

incentive award letter agreement financial

"RSUs granted on June 30, 2026 pursuant to an incentive award letter agreement"

vest financial

"The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

good reason financial

"termination of employment by the Issuer without cause or by the reporting person for good reason"

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:16 PM Accepted by SEC EDGAR 07/02/2026 - 05:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carmona Jose

(Last)

(First)

(Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE

NEW JERSEY

07974

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	06/30/2026		A	V	203,700⁽¹⁾	A	$0	938,076	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

	/s/ Lisa Kallebo, Attorney-in-Fact for Jose Carmona	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did ADC Therapeutics (ADCT) disclose about CFO Jose Carmona in this Form 4?

ADC Therapeutics disclosed that CFO Jose Carmona received 203,700 restricted stock units on June 30, 2026. These equity awards increase his direct holdings to 938,076 common shares, reflecting stock-based compensation rather than an open-market purchase or sale.

How many restricted stock units did ADC Therapeutics grant to its CFO?

ADC Therapeutics granted its CFO, Jose Carmona, 203,700 restricted stock units as of June 30, 2026. Each RSU represents a contingent right to receive one common share, subject to vesting conditions tied to time and certain employment termination scenarios.

When do Jose Carmona’s ADC Therapeutics RSUs vest?

The RSUs granted to Jose Carmona vest on the earlier of June 30, 2027 or his termination by ADC Therapeutics without cause, or his resignation for good reason. Vesting is conditioned on his continued employment with the company through the applicable vesting date.

How many ADC Therapeutics common shares does the CFO hold after this RSU grant?

Following the RSU award, Jose Carmona is reported to hold 938,076 ADC Therapeutics common shares directly. This figure reflects his position after the grant of 203,700 RSUs, which each convert into one share upon satisfying the vesting conditions described.

Is the ADC Therapeutics CFO Form 4 transaction a market buy or sell?

The Form 4 shows a grant or award acquisition, not a market trade. Jose Carmona received 203,700 restricted stock units at a price of $0.00 per unit as part of compensation, rather than buying or selling shares in the open market.

What conditions affect the vesting of ADC Therapeutics CFO RSUs?

The RSUs vest upon the earlier of June 30, 2027, or if ADC Therapeutics terminates the CFO without cause, or he resigns for good reason. Vesting remains subject to his continued employment with the issuer through the relevant vesting date under the incentive agreement.